Company intelligence / Profile preview

NeoSome Life Sciences

Billerica, Massachusetts, United Statesneosomels.com ↗

Ownership: Private
Employees: ~26
Development stage: Other

Overview

NeoSome Life Sciences primarily operates as a contract research organization offering in vitro and in vivo preclinical research services across multiple therapeutic areas, including oncology, infectious diseases, and pharmacology. Their internal drug discovery pipeline includes at least two small molecule programs targeting neoplastic diseases, with the most advanced asset in preclinical development for lung cancer. No clinical results have been reported as of May 2025.

Therapeutic areas: Oncology
Modalities: Small moleculeChemical drugs
Industry: Biotech

Drug pipeline

1 asset

NEOS-223

Preclinical

Partnerships

LNP Alliance (with four other companies to accelerate nanoparticle-based drug development; announced May 2025)

Beyond the preview

Go deeper on NeoSome Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoSome Life Sciences.

Explore the full profile